Who are Ranexa's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Naropin, Cerebyx, Decabid, ENCAINIDE, Tessalon, PIRMENOL.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ranolazine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Ranexa — Competitive Intelligence Brief

Ranexa (RANOLAZINE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anti-anginal [EPC]. Area: Metabolic.

marketed Anti-anginal [EPC] Sodium channel protein type 5 subunit alpha Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Ranexa (RANOLAZINE) — Menarini Intl. Ranexa works by blocking the sodium channels in heart muscle cells to reduce the amount of calcium that enters the cells during heart contractions.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ranexa TARGET	RANOLAZINE	Menarini Intl	marketed	Anti-anginal [EPC]	Sodium channel protein type 5 subunit alpha	2006-01-01
Naropin	ROPIVACAINE	Fresenius Kabi	marketed	Amide Local Anesthetic	Sodium channel protein type 5 subunit alpha	1996-01-01
Cerebyx	FOSPHENYTOIN	Pfizer	marketed	Anti-epileptic Agent	Sodium channel protein type 5 subunit alpha	1996-01-01
Decabid	INDECAINIDE	Eli Lilly	marketed		Sodium channel protein type 5 subunit alpha	1989-01-01
ENCAINIDE	ENCAINIDE		marketed	encainide	Sodium channel protein type 5 subunit alpha	1986-01-01
Tessalon	benzonatate	Generic (originally Pfizer)	marketed	Non-narcotic Antitussive [EPC]	Sodium channel protein type 5 subunit alpha	1958-01-01
PIRMENOL	PIRMENOL		marketed	pirmenol	Sodium channel protein type 5 subunit alpha

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2038-01-24 — Ranexa · 11510878 · Formulation · US
2038-01-24 — Ranexa · 12161761 · Formulation · US
2038-01-24 — Ranexa · 10898444 · Formulation · US

Sponsor landscape (Anti-anginal [EPC] class)

Menarini Intl · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ranexa — Competitive Intelligence Brief. https://druglandscape.com/ci/ranolazine. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab